“Patients with Lennox-Gastaut syndrome, a rare, severe form of epileptic encephalopathy, are frequently treatment resistant to available medications. No controlled studies have investigated the use of cannabidiol for patients with seizures associated with Lennox-Gastaut syndrome. We therefore assessed the efficacy and safety of cannabidiol as an add-on anticonvulsant therapy in this population of patients. Add-on cannabidiol is efficacious for the treatment of patients with drop seizures associated with Lennox-Gastaut syndrome and is generally well tolerated.“ https://www.ncbi.nlm.nih.gov/pubmed/29395273 http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30136-3/fulltext “This study is registered with ClinicalTrials.gov, number NCT02224690.”